Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
  • Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

KFF Medicare

The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The private plans that offer the Medicare Part D benefit – stand-alone drug plans and Medicare Advantage drug plans – are increasingly are competing on uneven terms, in part because the payment system

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
Next: China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

Related Stories

  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.